Presentation at HealthBIO Pitching Competition

1. Prateek Singh, CEO
Human biology replicated reliably
science@finnadvance.com

2. High cost and inefficient drug
development
Total cost: $2.6 billion
5k – 10 k
compounds
100 – 500
compounds
50 – 250
compounds
3-5
compounds
1
compound
HUMAN
5+ years 10+ years 12+ years
Prateek Singh, CEO
science@finnadvance.com

3. In-development Drugs Fail
in Clinical Trials
HUMAN
Drugs have different effects on 2D cell cultures and animals vs humans
→90 % of drugs validated on animals fail during human clinical trials
→Cell models and animal models do not adequately represent the human biology
→A large part of the total pharma R&D budget is spent on the failing drugs
Prateek Singh, CEO
science@finnadvance.com
Organ-on-Chip models allow significant saving in dollars (HUNDREDS OF MILLIONS) and
major timelines (YEARS)
Lancet. 2011 Jun
4;377(9781):1915

4. Impact of Finnadvance’s technology
In 5 years drug discovery costs are estimated to decrease 10-26% as a result
of this technology.
“If organ on chip was capable of identifying appropriate biomarkers, it would be
the “Holy Grail” of biotechnology”
Prateek Singh, CEO
science@finnadvance.com

5. Rare disease:
blood vessel
malformation
Patient-derived
cells
Our biomimetic
platform
Human disease-on-chip
Vascular anomaly organ-on-chip model
Prateek Singh, CEO
science@finnadvance.com

6. Organ-on-chip Market Forecast
2015 2020
Timescale (year)
2025
100B
10B
1B
100M
10M
MarketSize,Log.Scale
(USD)
Animal Research
In Vitro
3D In Vitro
Organ on a Chip
Prateek Singh, CEO
science@finnadvance.com
Ref : https://www.alliedmarketresearch.com/organ-on-chip-market
Ref : Organs on Chips 2017 report, March 2017, Yole Developpement

7. -M.Sc. Protein Tech and
Biochemistry, University of Oulu.
-B.Tech Biotechnology, National
institute of technology, India.
-5 peer reviewed publications.
-22 international presentations.
Prateek was born in India, and
after living in several countries
found a home in the scientific community of Oulu,
Northern Finland.
Prateek’s multi-disciplinary know-how was needed for
an EU Project aiming to uncover core mechanisms of
initiation and maintenance of Vascular Anomalies. The
study would be done on the Organ-on-Chip platforms
he would build. He founded Finnadvance to
commercialize this innovation and make drug discovery
faster and cheaper, while eliminating the use of
laboratory animals.
Prateek is a huge fan of science. He is extremely proud
of having worked on projects funded by NASA, ESA,
the Academy of Finland and TEKES.
Prateek Singh
CEO & Founder
Jari Moilanen
COOMinna Kihlström
CSO
Tuan Nguyen
CTO
Tuomas Nurmi
CMO
Highly Skilled & Diverse Team
Prateek Singh, CEO
science@finnadvance.com
-Ph.D. Vascular Biology, Uni. of Oulu
-M.Sc. Biochemistry and Cell Biology,
Oulu University.
-M.Sc. Thesis: Institute for Cancer
Research, University of Oslo, Norway.
-3 High-impact peer reviewed
publications. 3 Supervised Thesises.
Minna brings 8+ years cell culture and in
vitro research, 6+ years in vivo mouse
modelling and 7+ years microscopy
experience to the team.
-B.Eng & M.Sc in Biomedical Engineering
International University, Vietnam.
-Microtechnology research trainee,
University of Sheffield, UK.
-Ph.D. Studies in Biochemistry and
Molecular medicine, University of Oulu.
-2 Peer reviewed publications, 4
international presentations.
Tuan is a Biochemical Engineer who raised 2
research funding before finishing his M.Sc.
He has also won 2 young entrepreneur
competitions.
-M.Sc. Marketing,
Helsinki University.
-Lean Six Sigma Green Belt.
-MBA Studies.
10+ years Customer Operation
Manager of large accounts in
B2B Sales and 12+ years of
team management. Jari brings a
lot of seniority to the team.
-M.Sc. Biochemistry, University
of Oulu.
-1 Peer reviewed pulication, 1
international presentation.
Intellectual property rights
course and first patent filed in
2020.
Experience in teaching dance,
English and elementary school.

8. www.finnadvance.com
Prateek Singh, CEO
science@finnadvance.comCopy protected with Online-PDF-No-Copy.com